Hutchison China MediTech Limited (LON:HCM)‘s stock had its “buy” rating reaffirmed by research analysts at Beaufort Securities in a research note issued on Friday.

Separately, Panmure Gordon reiterated a “buy” rating and issued a GBX 3,530 ($44.90) price target on shares of Hutchison China MediTech Limited in a report on Thursday, June 22nd.

Shares of Hutchison China MediTech Limited (HCM) remained flat at GBX 3612.50 during midday trading on Friday. 59,532 shares of the company were exchanged. Hutchison China MediTech Limited has a 52-week low of GBX 1,760.00 and a 52-week high of GBX 3,690.00. The firm’s market capitalization is GBX 2.19 billion. The firm’s 50-day moving average is GBX 3,246.84 and its 200 day moving average is GBX 2,720.55.

ILLEGAL ACTIVITY WARNING: This article was originally published by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/07/01/hutchison-china-meditech-limiteds-lonhcm-buy-rating-reaffirmed-at-beaufort-securities.html.

About Hutchison China MediTech Limited

Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.

Receive News & Ratings for Hutchison China MediTech Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech Limited and related companies with MarketBeat.com's FREE daily email newsletter.